Immunolocalization of transcription factor NF-κB in inclusion-body myositis muscle and at normal human neuromuscular junctions

Neuroscience Letters

Volumn 254, Issue 2, 1998, Pages 77-80

  Yang, Chih Chao ^a   Askanas, Valerie ^a   King Engel, W ^a   Alvarez, Renate B ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Immunocytochemistry; Inclusion body myositis; Muscle diseases; Neuromuscular junctions; Nuclear factor B; Oxidative stress

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL TISSUE; ARTICLE; CELL INCLUSION; CONTROLLED STUDY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; MUSCLE BIOPSY; MYOSITIS; NEUROMUSCULAR SYNAPSE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, IMMUNOELECTRON; MUSCLE FIBERS; MUSCLES; MYOSITIS, INCLUSION BODY; NECROSIS; NEUROMUSCULAR JUNCTION; NF-KAPPA B; REFERENCE VALUES; TISSUE DISTRIBUTION;

EID: 0032566756     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00657-0     Document Type: Article

References (22)

1. Askanas V., Engel W.K. New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr. Opin. Rheumatol. 7:1995;486-496.
2. Askanas, V. and Engel, W.K., Newest approaches to diagnosis and pathogenesis of sporadic inclusion-body myositis and hereditary inclusion-body myopathies, including molecular pathologic similarities to Alzheimer disease. In V. Askanas, G. Serratrice and W.K. Engel (Eds.), Inclusion-Body Myositis and Myopathies, Cambridge University Press, Cambridge, UK, 1998, pp. 3-78.
3. Askanas V., Engel W.K. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Diseases of oxidative stress and aging? Arch. Neurol. 55:1998;915-920.
4. Askanas V., Alvarez R.B., Engel W.K. β-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann. Neurol. 34:1993;551-560.
5. Askanas V., Alvarez R.B., Mirabella M., Engel W.K. Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann. Neurol. 39:1996;389-391.
6. Askanas V., Sarkozi E., Alvarez R.B., McFerrin J., Engel W.K., Siddique T. Superoxide dismutase-1 (SOD1) gene and protein in vacuolated muscle fibers of sporadic inclusion-body myositis (s-IBM), hereditary inclusion-body myopathy (h-IBM), and cultured human muscle after β-amyloid precursor protein (βAPP) gene transfer. Neurology. 46:1996;487.
7. Baeuerle P.A., Henkel T. Function and activation of NF-K in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
8. Baeuerle P.A., Baltimore D. NF-κ: ten years after. Cell. 87:1996;13-20.
9. Boissière F., Hunot S., Faucheux B., Duyckaerts C., Hauw J.-J., Agid Y., Hirsch E.C. Nuclear translocation of NF-κB in cholinergic neurons of patients with Alzheimer's disease. NeuroReport. 8:1997;2849-2852.
10. Broccolini A., Engel W.K., Alvarez R.B., Thomas C.E., Yang C.-C., Askanas V. Possible pathogenic role of malondialdehyde, a toxic product of lipid peroxidation, in inclusion-body myositis. Neurology. 50:1998;367-368.
11. Engel W.K. Muscle biopsies in neuromuscular diseases. Pediatr. Clin. N. Am. 14:1967;963-995.
12. Grilli M., Goffi F., Memo M., Spano P. Interleukin-1β and glutamate activate the NF-κB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J. Biol. Chem. 271:1996;15002-15007.
13. Haginoya K., Alvarez R.B., Engel W.K., Askanas V. Light- and electron-microscopic immunolocalization of interleukins 1α, 1β and 6 in vacuolated muscle fibers of sporadic inclusion-body myositis (s-IBM). Neurology. 48:1997;126.
14. Helenius M., Hanninen M., Lehtinen S.K., Salminen A. Aging-induced upregulation of nuclear binding activities of oxidative stress responsive NF-KB transcription factor in mouse cardiac muscle. J. Mol. Cell Cardiol. 28:1996;487-498.
15. Kaltschmidt C., Kaltschmidt B., Henkel T., Stockinger H., Baeuerle P.A. Selective recognition of the activated form of transcription factor NF-κB by a monoclonal antibody. Biol. Chem. Hoppe-Seyler. 376:1995;9-16.
16. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., Kaltschmidt C. Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA. 94:1997;2642-2647.
17. Mirabella M., Alvarez R.B., Bilak M., Engel W.K., Askanas V. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion body myopathies. J. Neuropathol. Exp. Neurol. 55:1996;774-786.
18. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-κB. Annu. Rev. Cell Biol. 10:1994;405-455.
19. Suzuki T., Mitake S., Okumura-Noji K., Yang J.P., Fujii T., Okamoto T. Presence of NF-κB-like and IKB-like immunoreactivities in postsynaptic densities. NeuroReport. 8:1997;2931-2935.
20. Terai K., Matsuo A., McGeer P.L. Enhancement of immunoreactivity for NF-κB in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res. 735:1996;159-168.
21. Verma I.M., Stevenson J.K., Schwarz E.M., Antwerp D.V., Miyamoto S. Rel/NF-κB/IκB family: intimate tale of association and dissociation. Gene Dev. 9:1995;2723-2735.
22. Yang C.-C., Alvarez R.B., Engel W.K., Askanas V. Increase of nitric oxide syntheses and nitrotyrosine in inclusion-body myositis. NeuroReport. 8:1996;153-158.